inviongroup.comCrawled Nov 21, 2026
Invion produced a new topical and intravenous product suitable for use in skin cancer, infectious diseases and solid tumours, such as those present in ovarian, prostate and lung cancers.
Similar to the agreement with Hanlim Pharma Co., Ltd., Dr.inB will fund all Proof-of-Concept in vitro and/or in vivo studies. Invion retains all rights to the technology, including any new IP that may emerge from the collaboration.
Each photosensitising agent or drug is activated by light of a specific wavelength, which in turn determines how far the light can travel into the body to address specific cancer types.
A study by Prof Ramsay at the Peter MacCallum Cancer Centre found that combining INV043 with an immune checkpoint inhibitor eliminated tumors in 80% of mice with anal cancer, compared to a 12.5% response rate for standalone ICI therapy.
The second Proof-of-Concept study using INV043 API undertaken in October 2021 produced an unexpected result, according to Dr Andrew Stephens from Hudson Institute.
He is also the Co-Founder of Chronic Airway Therapeutics, a clinical stage firm focused on the treatment of respiratory diseases, and an Advisory Board Member at Stanford Medicine’s Center for Asian Health Research and Education (CARE).
He is a globally recognised expert in cancer biology and translational medicine, with over 40 years of research experience. He has made significant contributions to the development of novel therapies in oncology.
Director Business Development, Starpharma
Invion is a clinical-stage life-science company developing Photosoft technology for treating cancers and infectious diseases in human and animal health. It holds exclusive global rights to Photosoft for multiple cancer indications and worldwide rights for HPV, periodontal, and non-cancer eye diseases.
Invion’s board follows international best practices and the ASX Corporate Governance Council’s guidance to develop and improve its governance framework.
Invion Limited Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000 P: +61 3 9692 7222
Invion is an Australian life-sciences company advancing Photodynamic Therapy (PDT) for cancer treatments. It leads global research and development of Photosoft technology, holding exclusive rights for multiple cancer and non-cancer disease indications in human and animal health.